Next Article in Journal / Special Issue
ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
Previous Article in Journal
Isolation and Characterization of Nanobodies against a Zinc-Transporting P-Type ATPase
Article Menu

Export Article

Open AccessArticle
Antibodies 2018, 7(4), 40;

Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody–Drug Conjugate Modifications

Catalent Biologics, 2600 Hilltop Drive, Richmond, CA 94806, USA
Authors to whom correspondence should be addressed.
Received: 19 October 2018 / Revised: 12 November 2018 / Accepted: 13 November 2018 / Published: 16 November 2018
(This article belongs to the Special Issue Antibody-Drug Conjugate)
Full-Text   |   PDF [1804 KB, uploaded 16 November 2018]   |  


We hypothesized that systematic liquid chromatography-tandem mass spectrometry investigations of an antibody–drug conjugate (ADC), its small and large molecular components, and surrogate small-molecule conjugates might comprise a simple and efficient approach for the extended characterization of ADCs. Furthermore, we envisioned that results from this work might allow us to assign specific composition changes in the ADC based on monoisotopic mass shifts of conjugatable modifications as detected in the surrogate small-molecule conjugates. We tested our hypothesis with a case study using an aldehyde-tag-based ADC conjugated to a noncleavable linker bearing a maytansine payload. Nearly quantitative bioconversion from cysteine to formylglycine was observed in the monoclonal antibody, and bioorthogonal conjugation was detected only on the formylglycine residues in the ADC. Using our method, both conjugatable and nonconjugatable modifications were discovered in the linker/payload; however, only conjugatable modifications were observed on the ADC. Based on these results, we anticipate that our approach to systematic mass spectrometric investigations can be successfully applied to other ADCs and therapeutic bioconjugates for investigational new drug (IND)-enabling extended characterization. View Full-Text
Keywords: antibody–drug conjugate; ADC; biologic; analytical characterization; SMARTag® antibody–drug conjugate; ADC; biologic; analytical characterization; SMARTag®

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Linz, T.; Yeo, D.; Hong, Q.; Zmolek, W.; McFarland, J.; Barfield, R.M.; Haskins, W.E.; Rabuka, D. Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody–Drug Conjugate Modifications. Antibodies 2018, 7, 40.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top